We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

172 hedge funds and large institutions have $587M invested in Arbutus Biopharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $4.77M

47% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 15

22% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 45

9% more capital invested

Capital invested by funds: $536M → $587M (+$50.5M)

4% more funds holding

Funds holding: 166 → 172 (+6)

1.8% more ownership

Funds ownership: 61.64% → 63.45% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
172
Holders Change
+6
Holders Change %
+3.61%
% of All Funds
2.09%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
22
Increased
55
Reduced
45
Closed
15
Calls
$14.3M
Puts
$4.77M
Net Calls
+$9.55M
Net Calls Change
+$298K

Top Buyers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
+$11.3M
2
Morgan Stanley
Morgan Stanley
New York
+$10.1M
3
State Street
State Street
Massachusetts
+$8.14M
4
TSC
Two Seas Capital
New York
+$7.19M
5
UBS AM
UBS AM
Illinois
+$4.01M

Top Sellers

Rank Fund Capital Flow
1
FC
Foursixthree Capital
New York
-$8.98M
2
Goldman Sachs
Goldman Sachs
New York
-$6.45M
3
FCM
FourWorld Capital Management
New York
-$4.63M
4
Aberdeen Group
Aberdeen Group
United Kingdom
-$3.63M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
X
126
Xponance
Pennsylvania
$57.1K +$360 +80 +0.7%
PI
127
PFG Investments
New York
$52.9K -$11.2K -2,500 -19%
Belvedere Trading
128
Belvedere Trading
Illinois
$51.6K +$48.2K +10,721 New
FRA
129
Front Row Advisors
California
$50.5K – – –
CWM
130
CIBC World Markets
New York
$48.2K +$45K +10,015 New
Pathstone Holdings
131
Pathstone Holdings
New Jersey
$48.1K -$5.32K -1,184 -11%
CWP
132
Cyndeo Wealth Partners
Florida
$48.1K – – –
Mirae Asset Global Investments
133
Mirae Asset Global Investments
South Korea
$45K +$8.7K +1,935 +26%
TRCT
134
Tower Research Capital (TRC)
New York
$38.5K -$21.1K -4,687 -37%
EB
135
Eastern Bank
Massachusetts
$24.1K – – –
AB
136
Amalgamated Bank
New York
$23K -$1.29K -286 -6%
SPIA
137
Steward Partners Investment Advisory
New York
$19.2K – – –
GFM
138
GF Fund Management
China
$18.2K -$1.56K -346 -8%
CIAM
139
Caitong International Asset Management
Hong Kong
$15.1K +$14.1K +3,134 New
Nisa Investment Advisors
140
Nisa Investment Advisors
Missouri
$12.7K – – –
S
141
SignatureFD
Georgia
$12.3K – – –
BNP Paribas Asset Management
142
BNP Paribas Asset Management
France
$12K +$2.1K +468 +24%
Carson Wealth (CWM LLC)
143
Carson Wealth (CWM LLC)
Nebraska
$11K +$49 +11 +0.5%
AF
144
Allworth Financial
California
$9.83K +$8.67K +1,928 +1,677%
SAM
145
Smartleaf Asset Management
Massachusetts
$7.99K – – –
SCM
146
Sterling Capital Management
North Carolina
$7.37K +$2.77K +617 +67%
AW
147
Avion Wealth
Texas
$7K – – –
US Bancorp
148
US Bancorp
Minnesota
$6.98K – – –
AAP
149
Arax Advisory Partners
Colorado
$5.93K +$5.54K +1,233 New
PA
150
Parallel Advisors
California
$5.79K – – –
4 5
6
7 8

ABUS Hedge Fund Activity: Q4 2025 in Review

172 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2025, worth a combined $587M — up 9.4% from $536M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ABUS positions and 15 closed out — a net gain of 7 holders — while 55 added to existing stakes and 45 trimmed.

The largest buyer was ADAR1 Capital Management, adding an estimated $11.3M. The largest seller was Foursixthree Capital, exiting entirely with an estimated $8.98M sold.

  • 172 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2025, up from 166 in Q3 2025.
  • Funds reported $587M of Arbutus Biopharma stock for Q4 2025, up 9.4% quarter-over-quarter.
  • 22 funds opened new Arbutus Biopharma positions in Q4 2025 and 15 closed out, a net change of +7 holders.
  • The largest Arbutus Biopharma buyer in Q4 2025 was ADAR1 Capital Management, an estimated $11.3M added.
  • The largest Arbutus Biopharma seller in Q4 2025 was Foursixthree Capital, an estimated $8.98M sold.

Based on aggregated 13F filings for Q4 2025.